Peter J Stein, PhD, DC

In a retrospective international multicenter analysis, researchers assessed the prognostic effect of different degrees of hematoma expansion in patients with intracerebral hemorrhage.

Researchers sought to apply the clinical trial eligibility criteria for lecanemab and aducanumab treatment to patients with early AD from the MCSA study and assessed the generalizability of anti-amyloid treatment.